Snipr Biome takes aim at antibiotic resistant bacteria in phase I trial

Danish biotech company Snipr Biome, which is developing a new type of antibiotics using the gene-editing tool CRISPR, is sending its first candidate to clinic. ”It’s a huge day for us,” says CEO Christian Grøndahl.

by andreas lønstrup, translated by daniel pedersen

Danish biotech firm Snipr Biome announced on Wednesday that the first dose had been administered in a phase I trial with a potentially preventive treatment against E.coli infections in the gut.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles

Receive our daily newsletters

Access our app

Get full access for you and your coworkers

Start a free company trial today

Snipr Biome brings first candidate to human trial
For subscribers
FDA fast-tracks Snipr Biome's primary candidate
For subscribers
Snipr Biome chose clinical debut in CRISPR-ready USA
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Pharma & biotech

Novo Nordisk sets new record as market value surpasses USD 650bn

Each share in Novo Nordisk now costs over USD 145.

Wegovy approved in China

Novo Nordisk announces USD 4.1bn factory expansion in North Carolina

Pharma & biotech

UK court gives NHS green light to claim damages against Lundbeck

For subscribers

Albert Bourla, CEO of Pfizer, announced on Monday that the company is testing three potential weight loss drugs.

Pharma & biotech

Pfizer is testing three new weight loss candidates

For subscribers

Pharma & biotech

Teva to launch generic copy of Novo Nordisk drug in the US

Pharma & biotech

FDA accepts Lundbeck's application for Rexulti as supplementary PTSD treatment

Pharma & biotech

Eli Lilly appoints Nordic Head of Public Affairs

For subscribers

Wegovy approved in China
Novo Nordisk’s weight loss drug Wegovy has been approved for the treatment of severe obesity in China.
Novo Nordisk announces USD 4.1bn factory expansion in North Carolina
After months of speculation, Novo Nordisk has formally announced its plans to expand production facilities in Clayton.
Zealand Pharma is very open to partnership after promising obesity data
The company’s weight-loss drug Petrelintid has just delivered positive results.
Underdog obesity drug performs well in Phase II study
Altimmune has shown that the company’s weight loss drug pemvidutid predominantly provides weight loss from lost fat mass, rather than muscle.
For subscribers
ALK withdraws Chinese application for allergy tablet and raises guidance
The company now expects revenue growth of 12-15%.
For subscribers
Novo Nordisk tightens security after fire: "Until now it was built on trust"
After a fire and the discovery of undocumented workers at the site, security guards are being hired at Novo Nordisk’s future factory in Kalundborg.
For subscribers

Pfizer is testing three new weight loss candidates

Two of the experimental drugs are GLP-1 agents.

For subscribers

Pharma & biotech

Teva to launch generic copy of Novo Nordisk drug in the US

Sales of type 2 diabetes drug Victoza dropped last year.

Pharma & biotech

UK court gives NHS green light to claim damages against Lundbeck

Although it is more than ten years since the European Commission ruled that Lundbeck entered into illegal pay-for-delay agreements regarding the drug Citalopram, the NHS can still claim compensation.

For subscribers

Pharma & biotech